Document is current

Any future updates will be listed below

854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.854

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark